Department of Paediatrics, Aarhus University Hospital Skejby, Denmark.
APMIS. 2012 Oct;120(10):794-801. doi: 10.1111/j.1600-0463.2012.02910.x. Epub 2012 May 15.
Taurolidine has demonstrated inhibition of biofilm formation in vitro. The aim of this study was to compare the effect of catheter locking with taurolidine vs heparin in biofilm formation in central venous catheters. Forty-eight children with cancer were randomized to catheter locking by heparin (n = 22) or taurolidine (n = 26), respectively. After removal, catheters were examined by standardized scanning electron microscopy to assess quantitative biofilm formation. Biofilm was present if morphologically typical structures and bacterial cells were identified. Quantitative and semi-quantitative cultures were also performed. Biofilm was identified in 23 of 26 catheters from the taurolidine group and 21 of 22 catheters from the heparin group. A positive culture was made of six of the catheters locked with taurolidine and heparin, respectively (p = 0.78). The rate of catheter-related bloodstream infections (CRBSI) was 0.1 per 1000 catheter-days using taurolidine and 0.9 per 1000 catheter-days using heparin (p = 0.03). This randomized trial confirmed that the use of taurolidine as catheter-lock compared with heparin reduced the rate of CRBSIs; this reduction was not related to a reduction in the intraluminal biofilm formation and the rate of bacterial colonization detected by scanning electron microscopy in the two groups.
替考拉宁已证明可抑制生物膜的体外形成。本研究旨在比较替考拉宁与肝素对中心静脉导管生物膜形成的导管锁定作用。将 48 例癌症患儿随机分为肝素(n=22)或替考拉宁(n=26)导管锁定组。导管取出后,采用标准化扫描电子显微镜检查评估定量生物膜形成情况。如果形态典型结构和细菌细胞被识别,则存在生物膜。还进行了定量和半定量培养。替考拉宁组 26 个导管中有 23 个存在生物膜,肝素组 22 个导管中有 21 个存在生物膜。替考拉宁和肝素分别有 6 个导管的培养呈阳性(p=0.78)。使用替考拉宁的导管相关血流感染(CRBSI)发生率为每 1000 个导管日 0.1 例,使用肝素的发生率为每 1000 个导管日 0.9 例(p=0.03)。这项随机试验证实,与肝素相比,替考拉宁作为导管封管可降低 CRBSI 的发生率;这种降低与两组扫描电子显微镜检测到的管腔内生物膜形成和细菌定植率降低无关。